

tor ever be distracted by the research going on in the lab.

**Richard S. Jope**

Department of Psychiatry, Sparks Center 1057, University of Alabama, Birmingham, AL 35294-0017, USA. E-mail jope@uab.edu

### Clarification of AstraZeneca's R&D Strategies

In the table accompanying the News Focus article "Drug research endures the pains of globalization" by Joanna Rose and Annika Nilsson (10 Dec., p. 2063), inaccuracies regarding AstraZeneca's research and development (R&D) strategy in Sweden give a wrong view of our intentions. Sweden is one of our three key bases within R&D, and we will continue to invest in our Swedish R&D operations, which are located in Södertälje, Lund, and Mölndal.

To clarify and expand on the information in the article's table, AstraZeneca's R&D headquarters will remain at Södertälje, which is also the main site for the therapy area of pain control, as the table indicates. Discovery and development R&D will remain at Södertälje for both central nervous system and pain control research. Only some central nervous system R&D is moving to Wilmington, Delaware, a decision that was made before Astra and Zeneca's merger. In addition, the safety assessment division will remain in Södertälje, and, in a few months, a new investment in biotechnology belonging to the global Enabling Science and Technology organization will be in operation.

Reference to cancer research being located at Alderley Park in the United Kingdom is correct; however, it was never located in Sweden, as suggested by the title of the table.

AstraZeneca's asthma research will be conducted at both Charnwood in the United Kingdom and at Lund, as indicated in the table, but Lund will be the main site for R&D in respiratory diseases and inhalation, not just a site for "some asthma research."

And finally, Mölndal, which is not mentioned in the article or table, is our largest R&D site in Sweden with 1500 employees, and it is the main site for therapy areas for gastrointestinal and cardiovascular R&D, not Södertälje, as the table suggests. Mölndal will also be the site for a new research center for Global Enabling Science Technology Biology, Informatics and Chemistry.

**Claes Wilhelmsson\***

AstraZeneca, S-151 85 Södertälje, Sweden

\*Executive director of Research and Development

### Editors' note

The inaccuracies referred to in the above letter were restricted to the table that accompanied the article. They were inadvertently

introduced during editing and not the responsibility of the authors.

### Cooperating on Childhood Cancer

The content and tone of the News Focus article "No meeting of minds on childhood cancer" by Jocelyn Kaiser (3 Dec., p. 1832) seem focused on rekindling tensions between two government agencies when such tensions have been in large measure resolved. Indeed, the Environmental Protection Agency (EPA) and the National Cancer Institute (NCI) are working closely together in many areas related to environmental determinants of cancer, including cancer in children, and are in agreement on important issues related specifically to childhood cancer, including (i) that rates of childhood cancer have remained relatively stable since 1985; (ii) that the increases occurring before 1985 are not well understood, although better diagnosis and reporting likely contribute to some portion of the increase; (iii) that ongoing monitoring of trends in incidence is essential; and (iv) that well-designed studies are needed to make progress in understanding the causes of childhood cancers.

NCI and EPA co-chair the Childhood Cancer Working Group, one of four working groups established as a part of President Bill Clinton's Task Force on Environmental Health Risks and Safety Risks to Children. Through this and other partnerships, the EPA and NCI are working to develop and implement joint initiatives in cancer and the environment, and lines of communication have widened to facilitate these interactions. The Task Force has established a database of children's environmental health research projects, as noted in Kaiser's article. Major initiatives of the Childhood Cancer Working Group that are focused on childhood leukemias and brain tumors, on pre-clinical models, and on environmental exposure measures are in the planning stages. These initiatives indicate that NCI and EPA, in collaboration with other federal agencies, are committed to working together to better understand the etiology of childhood cancer.

**Susan M. Sieber\***

National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA

**Steven K. Galson†**

Environmental Protection Agency, 401 M Street, SW, Washington, DC 20460, USA

\*Co-chair, Childhood Cancer Work Group, and associate director for Special Projects

†Former co-chair, Childhood Cancer Work Group, and director, Office of Science Coordination and Policy

## Custom Shotgun Libraries




- Custom Libraries from Cosmids, BACs and Genomes
- M13 or pUC Vectors
- Ready in 1-2 Weeks
- Clones Shipped in 96 or 384-Well Plates



### Custom Gridding & Arraying

- Arraying of Libraries to Nylon Filters
- Up to 29,000 Double Spotted Clones/Filter



### Shotgun Sequencing

- Clones Picked & Prepped
- High Throughput Sequencing & Assembly
- Full-Length Sequencing

**Call For Pricing on Your Project Today**

**SEQWRIGHT**

DNA SEQUENCING

Circle No. 21 on Readers' Service Card

**THE FASTEST SERVICE IN THE INDUSTRY, WITH GUARANTEED RESULTS.**

Tel: 1-800-720-4363

Web: [www.seqwright.com](http://www.seqwright.com)